Full-Time

Video Editor

Creative Performance

Eucalyptus

Eucalyptus

501-1,000 employees

Global telehealth platform offering digital clinics

No salary listed

New South Wales, Australia

In Person

On-site in New South Wales, Australia.

Category
Art, Graphics & Animation (1)
Required Skills
A/B Testing
Animation
Video Editing

Get referred to Eucalyptus

See people who can refer or advise you

Requirements
  • 3-5 years editing at pace, in-house, agency, or freelance, with a reel that shows range, output, and a clear feel for performance-driven content
  • Stack-agnostic and outcome-focused. You use what the job needs - one tool, three tools, whatever - and don't evangelise software.
  • Performance-literate. You understand hooks, pacing, and retention. You read your edits as ad units as much as creative pieces, and you care that they work.
  • Keen to learn. You'll be working alongside some of the best performance marketers in Australia, and you want to soak it up. You ask good questions, take feedback well, and get sharper every month.
  • Platform-native. You instinctively know how content should feel on each surface, and you can hold the line on craft while moving at social speed.
  • Strong shooting fundamentals. Composition, light, sound, and a calm hand on a smaller set. You know what's worth shooting and what isn't.
  • Fast, organised, and a clear communicator. You ship without being prompted and never let work go quiet.
  • Customer intuition. You understand who Juniper's customers are and what resonates with them. You can spot the moments and angles that will land.
  • Empathetic on set. Juniper operates in a sensitive category. You create a comfortable environment for talent, particularly when working on content related to women's health.
  • Commercially minded. You care that your work performs. Feedback from the data matters as much to you as feedback from the creative team.
  • Resilient and resourceful. You thrive in high-volume environments and don't need perfect conditions to deliver great work.
  • Passionate about the mission. You want to make work that genuinely supports women through their health journeys.
Responsibilities
  • Editing for performance. Owning post end to end - cut, sound, colour, captions, motion, exports - across high-volume paid social, organic, and brand work. You know the rules of best practice on each platform, and you've got the brains and the craft to execute them at speed.
  • Shooting alongside the team. Supporting our in-house production days, capturing footage with the creative team, and running smaller solo shoots when the brief calls for it. You're not a DOP - but you'll get to learn from some of the best in the country on bigger shoot days.
  • BTS and social shooter. You see the value in a quick lo-fi idea shot fast. When inspiration hits, you point first and ask questions later - the behind-the-scenes beat, the genuine reaction, the unexpected angle that ends up doing numbers.
  • Cutting native to platform. What works as a TVC won't work on Reels, and what works on Reels won't work on TikTok. You shoot and edit with the channel in mind from the first frame.
  • Working with the data. You partner with the Performance and Social teams to understand what's converting, what's stalling, and why. You iterate on what's working and bring an informed point of view to the next round of work.
  • Communicating clearly. You give status without being chased. You flag blockers early. You move fast, and you make it easy for the people around you to move fast too.
  • Bringing ideas, not just execution. You contribute creative thinking to briefs, suggest references, push back constructively, and improve the work through the lens of what actually performs.

Eucalyptus.vc runs digital healthcare clinics as a global telehealth service focused on patient-first care. Patients connect with certified practitioners for remote consultations, treatments, and ongoing care entirely through the online platform. The service provides end-to-end care in one digital ecosystem, from initial visit to follow-up, with revenue from fees for these clinical services. The company aims to make safe, effective care accessible worldwide by leveraging its global team of over 400 professionals to operate the clinics.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$139.7M

Headquarters

Sydney, Australia

Founded

2019

Get referred to Eucalyptus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Hims & Hers closed the acquisition on 2026-06-02, validating Eucalyptus's scale.
  • Run-rate revenue exceeded $450 million and 2025 growth stayed triple-digit.
  • Consultmed referrals launched in March 2026, expanding GP-sourced Juniper demand.

What critics are saying

  • Hims & Hers bought Eucalyptus on 2026-02-19, ending standalone employer upside.
  • Earnouts through early 2029 tie employee value to Hims & Hers targets.
  • Telehealth weight-loss rivals and regulators can crush Juniper margins quickly.

What makes Eucalyptus unique

  • Juniper and Pilot give Eucalyptus category-specific consumer brands across five countries.
  • Tim Doyle built local regulatory playbooks, enabling Hims & Hers' June 2026 integration.
  • ACHS accreditation and 20+ outcome studies signal clinically disciplined operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Employee Stock Purchase Plan

Flexible Work Hours

Hybrid Work Options

Wellness Program

Mental Health Support

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Stock Options

Company Equity

Conference Attendance Budget

Professional Development Budget

Birthdays?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

-3%
Schaeffer's Investment Research
Feb 20th, 2026
Geopolitical Tensions Resurface Amid Volatile Week

Geopolitical tensions resurface amid volatile week. The S&P 500 and Nasdaq boast healthy weekly gains. Assistant Editor Feb 20, 2026 at 2:09 PM Despite Tuesday's rough start, all three major indexes closed higher, the Nasdaq Composite (IXIC) snapping its four day-losing streak. Stocks held steady on Wednesday after receiving a boost from big tech gains, while the Federal Reserve's January meeting minutes held investor attention. On Thursday, the Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) both snapped three-day win streaks, while the Nasdaq also faced trouble; these losses slid right past traders as focus remained on geopolitical tensions and weekly jobless claims. The Nasdaq and S&P 500 are pacing for weekly gains, after the Supreme Court dismissed President Donald Trump's tariffs and lifted Wall Street's spirits. Stock movers this week. There were plenty of headlines for investors to unpack over the holiday-shortened week. Norwegian Cruise Line Holdings (NCLH) popped after reports that Elliott Investment Management has built an over 10% stake. In M&A news, Masimo (MASI) stock soared after reports that it will be acquired by Danaher (DHR) for $10 billion, while Hims & Hers Health (HIMS) announced its $1.15 billion acquisition of Australian digital health company Eucalyptus. In biotech news this week, the U.S. Food & Drug Administration (FDA) accepted Moderna's (MRNA) flu vaccine application for review, while Grail (GRAL) stock plummeted after the company's three-year cancer screening trial failed to meet its main goal. Meanwhile, Walmart's (WMT) disappointed earnings outlook contributed to pessimism on Thursday. Commodities, rare earths in focus. Rising oil prices were a highlight this week amid U.S.-Iran tensions, with options bulls targeting the United States Oil Fund (USO). Meanwhile, Devon Energy (DVN) tapped a 17-month high after strong fourth-quarter results, while Melius Research upgraded Chevon (CVX), citing exploration upside. Even further, gold mining name Newmont (NEM) continued to charge higher before its fourth-quarter report. On the flip side, rare earths stock MP Materials (MP) plummeted to a one-month low. As goes february. The final week of the month is jam packed with key earnings reports, delayed economic data, speeches from several Federal Reserve officials, and more. For now, Schaeffer's Senior V.P. of Research Todd Salamone says to keep your eye on these S&P 500 names, while Senior Quantitative Analyst Rocky White breaks down Wall Street's "fear gauge."

The Wall Street Journal
Feb 19th, 2026
Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal

Hims & Hers Health has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion in an effort to expand its geographic reach.

Investing.com
Feb 19th, 2026
Hims & Hers stock rises after agreement to acquire Eucalyptus

Hims & Hers stock rises after agreement to acquire Eucalyptus. ByInvesting.com Published 02/19/2026, 06:54 AM (C) Reuters. Investing.com - Hims & Hers Health, Inc. (NYSE:HIMS) stock rose 7.8% Thursday morning after the company announced it has entered into a definitive agreement to acquire Eucalyptus, an international digital health leader with operations in Australia, the UK, Germany, Japan, and Canada. The acquisition, valued at up to $1.15 billion USD, will accelerate Hims & Hers' global expansion strategy while preserving its financial flexibility. The company will pay approximately $240 million in cash upon closing, with the remaining consideration structured as deferred payments over 18 months and additional earnout payments tied to financial targets through early 2029. Eucalyptus, which operates consumer brands including Juniper and Pilot, has served more than 775,000 customers and currently maintains an annual revenue run-rate exceeding $450 million USD. The company has demonstrated triple-digit YoY revenue growth in each quarter of calendar year 2025 while operating near profitability. "Healthcare challenges are global, and so is the demand for simpler, transparent, and more personalized healthcare," said Andrew Dudum, founder and CEO of Hims & Hers. "With Eucalyptus, we will not only enter new markets, we will expand our ability to serve customers globally, trusting local experts to be a key part of how we transform healthcare into a customer-first, personalized industry." Following the acquisition's completion, Eucalyptus CEO Tim Doyle will become SVP of International at Hims & Hers, overseeing the company's international business. Eucalyptus' portfolio of brands will transition into Hims & Hers over time. The transaction is expected to close during the middle of calendar year 2026, subject to regulatory approvals and other customary closing conditions. Hims & Hers plans to finance most of the acquisition using existing cash and future operating cash flows from its U.S. operations. Which stock should you buy in your very next trade? AI computing powers are changing the stock market. Investing.com's ProPicks AI includes dozens of winning stock portfolios chosen by our advanced AI. Year to date, 2 out of 3 global portfolios are beating their benchmark indexes, with 88% in the green. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%). Which stock will be the next to soar?

PR Newswire
Jul 28th, 2025
Amigo Partners with Eucalyptus to Scale AI-Powered Healthcare Delivery Across Global Telehealth Network

Amigo partners with Eucalyptus to scale ai-powered healthcare delivery across global telehealth network.

PR Newswire
Feb 4th, 2025
Lorikeet Secures $9M for AI Expansion

Lorikeet, an AI customer experience company, has secured an additional AUD 9 million in funding from Blackbird and existing investors, following a USD 5 million seed round last year. The funds will enhance Lorikeet's platform and expand its market presence in industries like healthcare and finance. Lorikeet's intelligent graph technology enables AI agents to handle complex support queries, improving customer satisfaction and support efficiency for clients like Eucalyptus and Magic Eden.